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Introduction
Cancer is one of the major causes of mortality in the world. Sur-gery, radiotherapy and chemotherapy are the most common ap-proaches for cancer treatment. Since radiotherapy and surgery 
are limited to local treatment of cancer which has not spread to nearby 
tissue, systemic chemotherapy is the main treatment for many types of 
cancer [1]. Distribution of drug in the body is non-selective and unde-
sired side effects are usually seen due to normal tissue damages. Con-
sidering the poor response of cancer to the chemotherapy agents, there 
exists an essential need to develop some certain ways to increase drug 
delivery efficiency and to reduce the side effects [2-6].
Nanoparticles are promising platforms to increase the chance of 
selective delivery of chemotherapeutic agents to cancer cells. To de-
Original
ABSTRACT
Background: Drug nano-carriers are one of the most important tools for targeted 
cancer therapy so that undesired side effects of chemotherapy drugs are minimized. 
In this area, the use of ultrasound can be helpful in controlling drug release from 
nanoparticles to achieve higher treatment efficiency.
Objective: Here, we studies the effects of ultrasound irradiation on the release 
profile of 5-fluorouracil (5-Fu) loaded magnetic poly lactic co-glycolic acid (PLGA) 
nanocapsules.
Methods:  5-Fu loaded magnetic PLGA nanocapsules were synthesized by mul-
tiple emulsification method. Particle size was measured by dynamic light scattering 
(DLS) and transmission electron microscope (TEM). The pattern of drug release was 
assessed with and without 3 MHz ultrasound waves at intensities of 0.3, 0.5 and 1 w/
cm2 for exposure time of 5 and 10 min in phosphate-buffered saline (PBS).
Results: The size of nanoparticles was about 70 nm. Electron microscope images 
revealed the spherical shape of nanoparticles. The results demonstrated that the inten-
sity and exposure time of ultrasound irradiation have significant effects on the profile 
of drug release from nanoparticles.
Conclusion:  It may be concluded that the application of ultrasound to control 
the release profile of drug loaded nanocapsules would be a promising method to 
develop a controlled drug delivery strategy in cancer therapy.
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velop good drug delivery carriers, it is desir-
able to have systems with good capability of 
drug loading, controlled release profile, high 
biological half-life and low toxicity [7, 8-11]. 
As a biocompatible drug carrier, iron oxide 
nanoparticles have recently received food and 
drug administration (FDA) approval and ex-
tensively utilized in the field of targeted che-
motherapy [8, 12]. On the other hand, there 
are many studies reporting that polymer-coat-
ed magnetic nanoparticles may have higher 
capabilities in the area of targeted drug deliv-
ery [13-15]. Polymers which are used to de-
sign and synthesize polymer-coated magnetic 
nanoparticles must have the unique properties 
of biocompatibility and biodegradation; poly 
lactic co-glycolic acid (PLGA) is one of the 
most important polymers in this area [7]. We 
have recently reported the synthesis and char-
acterization of a novel PLGA-based magnetic 
nanocapsule containing 5-floururacil (5-Fu) 
as an appropriate drug carrier [16]. Using an 
external magnetic field, we targeted this new 
nanocapsule towards colon tumors in vivo and 
reported significantly better results in com-
parison to 5-Fu alone. We also suggested the 
combination of magnetic drug targeting and 
ultrasound wave has significant effects on 
increasing the therapeutic ratio of magnetic 
nanocapsules [17, 18].
Ultrasound is considered a mediator for tar-
geted drug delivery through mechanical inter-
action with both drug carrier and cell mem-
brane [19]. The mechanical vibrations caused 
by interaction of ultrasound with environment 
can increase the movement of cell membrane 
in smaller scales which is called macro-mo-
lecular massage. This process can modify the 
properties of biological tissues such as the per-
meability of cell membrane. Moreover, mac-
ro-molecular massage can change the profile 
of drug release from nano-carriers [20]. The 
investigation done by Ninomiya et al. shows 
the rate of drug release for doxorubicin load-
ed temperature-sensitive liposome speeds up 
about 40 percent if liposome is exposed by 1 
MHz ultrasonic waves with nominal intensity 
of 0.5 W/cm2 for 2 min [21]. Burke et al. dem-
onstrated that the use of drug loaded PLGA 
and application of 1 MHz ultrasound radiation 
increased in-vivo tumor retardation rate rather 
than the free drug prescription [22]. In another 
study, Rappaport et al. incubated cancer cells 
with pluronic micelles containing Doxorubi-
cin. The incubated cells were exposed to 69 
KHz ultrasound at intensity of 2.3 W/cm2 for 
10 min. The growth of cells receiving both 
micelles and ultrasound was much slower 
than the cells receiving micelles alone [23]. 
In addition to these studies, we have recently 
studied the synergistic effects of 3 MHz ul-
trasound waves at intensity of 0.3W/cm2 and 
5-Fu loaded PLGA nanocapsules on colon 
tumor in vivo. It was demonstrated that com-
bination of nanocapsules with ultrasound irra-
diation significantly increased the therapeutic 
ratio rather than the prescription of the free 
drug alone [17]. We had an important question 
related to the effect of ultrasound parameters 
on the release rate of 5-Fu from PLGA nano-
capsules and finding a good response for this 
question motivated us to conduct the present 
study. Here, for the first time, we investigated 
how ultrasound parameters affect the release 
rate of a drug from nanocapsules designed for 
magnetic drug targeting. The original data ob-
tained from this study may be helpful to opti-
mize ultrasound parameters and to suggest an 
appropriate in-vivo scientific paradigm.
Material and Methods
Chemicals
5-Fu was purchased from Sigma Chemical 
Company (St Louis, MO, USA). PLGA poly-
mer (Resomer RG502H) was purchased from 
Boehringer–Ingelheim (Ingelheim, Germany). 
The mole ratio of glycolic acid to lactic acid in 
PLGA was 50:50 and its molecular weight was 
12000 g/mol. Ferrous chloride (FeCl2.4H2O), 
ferric chloride (FeCl3.6H2O), oleic acid, am-
monia solution (25 vol%), dichloromethane 
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(DCM), glycerin, span60 and tween60 were 
purchased from Merck Chemical Company 
(Darmstadt, Germany). All chemicals were 
used without further purification.
Nanocapsule Preparation
5-Fu-loaded magnetic PLGA nanocapsules 
were synthesized according to the method 
which has been recently reported by our re-
search group [16, 24]. Briefly, magnetic nano-
capsules were prepared using a modified O1/
W1/O2/W2 multiple emulsion solvent evapo-
ration procedure. Glycerin was used as a sur-
factant to stabilize the dispersed phase. First, 
20mg of magnetite nanoparticles (12 nm in 
diameter and modified by oleic acid) was dis-
persed in 0.5 ml of DCM to prepare a primary 
organic phase (O1) using an ultrasonic bath. 
Then, the inner aqueous solution was pre-
pared by dissolving 10 mg 5-Fu as a hydro-
philic drug and 15 mg tween60 as a surfactant 
in 1.5 ml of double-distilled water (W1). The 
magnetic dispersion (O1) was emulsified in 
the inner aqueous solution (W1) by ultrasoni-
cation using the sonicator probe at an output 
of 50W for 30 s in an ice-bath to obtain an 
O1/W1 emulsion (dispersion of magnetite). 
This primary emulsion was emulsified in an 
organic solution (O2) of the polymer (50 mg 
PLGA and 250 mg span 60 in 6 ml DCM) by 
ultrasonication for 30 s (50 W) in an ice-bath 
to obtain O1/W1/O2 double emulsion. Next, 
this double emulsion was immediately poured 
into 15 ml of W2 aqueous solution, which was 
made of 150 mg tween60 dissolved in 7.5 ml 
of distilled water and 7.5 ml of glycerin, and 
the mixture was ultrasonicated again for 30 s. 
The resulting multiple emulsion (O1/W1/O2/
W2) was diluted in 24 ml of aqueous solution 
composed of 12 ml distilled water and 12 ml 
glycerin under mechanical stirring, and the 
DCM was removed by solvent evaporation. 
The stirring was continued for a period of 3 h 
at room temperature to allow evaporation of 
the organic solvent. The resulting magnetic 
nanocapsules were cleaned by repeating the 
procedure of centrifuging and re-suspending 
in distilled water three times and were then 
collected with a magnet. Most of the non-en-
capsulated drug remained in the outer aqueous 
solution, and the remaining loosely adsorbed 
drug on the surface of the nanocapsules was re-
moved through washing with double-distilled 
water. Finally, the obtained nanocapsules were 
dried by freeze-drying and stored at 4˚C.
Determination of Particle Size 
and Morphology
The morphological investigation of 5-Fu-
loaded nanocapsules was performed using a 
Zeiss LEO 906 transmission electron micro-
scope (TEM). The nanocapsules were sus-
pended in distilled water and sonicated for 10 
min. A drop of the nanoparticle suspension 
was placed on a carbon coated grid. The grid 
was perfectly dried and observed under TEM 
at 100 kV. The size distribution and the effec-
tive diameter of nanocapsules were measured 
using a Brookhaven 90 plus Nanoparticle Size 
Analyzer (Brookhaven Instruments, Holts-
ville, NY, USA).
Determination of Drug Content and 
Encapsulation Efficiency
To evaluate drug concentration in a nano-
capsule, a UV absorption measurement was 
performed. 5-Fu concentration was calculated 
by application of Beer’s law in which the ab-
sorption is proportional to concentration. The 
drug content in the magnetic nanocapsules is 
defined as the ratio of the encapsulated drug 
to the total weight of solid magnetic nanocap-
sule. The encapsulation efficiency is defined 
as the ratio of the encapsulated drug content to 
the total amount of drug used for nanocapsule 
preparation. 
First, the solid (freeze-dried) nanocapsules 
were weighed (5 mg) and re-dissolved in 5 ml 
acetone (spectroscopy grade). Next, the insol-
uble magnetite particles were removed from 
the solution by magnetic separation. With re-
spect to Equation (1) which is a previously es-
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tablished calibration curve, the 5-Fu concen-
tration in the acetone solution was determined 
by UV absorption at a wavelength of 210 nm 
(characteristic absorption band of 5-Fu in ac-
etone):
Y= 2.9875x – 0.014, R2= 0.998                  (1)
Then, the amount of encapsulated drug in 
the nanocapsules was calculated according to 
Equations (2) and (3):
Drug Content = (weight of encapsulated drug 
in nanocapsules /weight of nanocapsules) 
 × 100                                                          (2)
Encapsulation Efficiency = (weight of encap-
sulated drug in nanocapsules/weight of initial 
loading of drug) × 100                                (3)
Experimental Setup
Study of Drug Release Profile in the 
Absence of US Irradiation
At first, the following calibration equation 
for 5-Fu in phosphate buffered saline (PBS) 
was obtained using dilution technique:
Y= 3.173x – 0.061, R2= 0.997                   (4)
where Y is 5-Fu concentration and X is ab-
sorbance at the wavelength of 269 nm. Then, 
in- vitro release of 5-Fu from magnetic nano-
capsules was studied in 0.01 M PBS (pH 7.4) 
using the dialysis method. The dialysis bag 
(molecular weight cut-off 12,400 Da) was 
soaked in preheated double-distilled water 
before use. A weighed amount of freeze-dried 
magnetic nanocapsules
(1 mg) was re-suspended in 1 ml PBS and 
transferred into a dialysis bag. Both ends of 
the tube were affixed with clamps. The bag 
was placed into 50 ml of PBS that acted as 
a release medium. The release study was per-
formed in an incubator shaker at 37 ˚C. At 
selected time intervals, the solution outside 
the dialysis bag was removed for UV–visible 
analysis and replaced with fresh buffer solu-
tion (Figure 1). Based on the absorbance of 
5-Fu at 269 nm, drug concentration was calcu-
lated using Equation (5):
Y= 3.173x – 0.061, R2= 0.997                    (5)
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Figure 1: (a) A schematic illustration and (b) an image of experimental setup when ultrasound 
was absent.
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In the study of drug release behavior, the 
cumulative amount of released drug was cal-
culated, and the percentage of released drug 
from the magnetic nanocapsules was plotted 
as a function of time.
Study of Drug Release Profile in the 
Presences of Ultrasound Irradiation
To investigate the effects of ultrasound expo-
sure on drug release profile, above procedure 
(the protocol mentioned in section 2.5.1) was 
similarly performed, but an additional pre-
treatment step was considered. The additional 
step was included (i) the insertion of nano-
capsules loaded dialysis bag in a customized 
container made of Plexiglas (Figure 2) and (ii) 
ultrasound irradiation to nano-suspension with 
different parameters using a plane circular 
transducer with an area of 1 cm2 operating at 3 
MHz in the continuous wave mode (Phyaction 
190i, Germany). Ultrasound power output was 
measured using the acoustic radiation force 
method (16, 24). A linear relationship between 
nominal intensity (I1) and measured intensity 
(I
2
) was obtained as demonstrated below:
I1= 0.942 I2+ 0.185, R² = 0.974                   (6)
The ratio of peak intensity to average inten-
sity (Ip/Ia) was calculated using the dye paper 
method [16, 24] and Kossoff approximation 
method which was found to be approximately 
5.
After ultrasound exposure, dialysis bag was 
removed from container and placed into 50 ml 
of PBS at 37˚C as a release medium, and sam-
ples were taken at pre-selected time intervals. 
Based on the status of ultrasound exposure to 
nanocapsules, 7 different groups were consid-
ered in this study (Table 1). Control group did 
not receive any ultrasound radiation. In other 6 
groups, nanocapsules were ultrasonicated for 
5 min and 10 min at various intensities from 
0.3 to 1 w/cm2. Samples were collected for 24 
hours and the absorption of each sample was 
measured through UV spectrophotometer Ray 
leight UV-1601 and then the cumulative re-
lease curves were plotted.
Statistical Methods
All experiments were conducted in tripli-
cate. Statistical analysis was performed by 
one-way ANOVA test and used the Tukey test 
at 95% confidence level as a post-test. Sta-
tistical analyses were performed using SPSS 
 
(a) 
(b) 
Figure 2: (a) A schematic illustration and (b) an image of experimental setup when ultrasound 
was present (inset: designed container).
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software (version 11). A value of P < 0.05 was 
considered statistically significant.
Results 
Nanoparticle Characteristics
DLS results revealed that nanocapsules had 
good monodispersity and their effective di-
ameter was about 70 nm (Figure 3). A typical 
TEM micrograph of magnetic nanocapsules is 
presented in Figure 4, the dark regions may 
correspond to the magnetic nanoparticles in-
corporated into PLGA nanocapsules. 
According to spectrophotometry studies and 
considering equations 2 and 3, drug content 
and encapsulation efficiency of synthesized 
nanocapsules were calculated which were 
5.8% and 46.4%, respectively.
Effects of Ultrasound Irradiation 
on Drug Release
Effect of Intensity
Figures 5a and 5b show the effect of ultra-
sound at different intensities on the rate of 
drug release from nanocapsules. Figure 5a il-
lustrates the effect of 5-minute ultrasound ir-
radiation of dialysis bag at different intensities 
on the rate of drug release from nanoparticles. 
The drug released 24 hours after sonication for 
1W/cm2 intensity (16.4± 0.93)% was almost 
3 fold higher than the control (5.8± 0.32)%. 
This signifies that sonication period and inten-
sity are the two parameters affecting the rate 
of drug release from nanoparticles. Figure 5b 
shows the effect of 10 min ultrasound irradia-
tion on drug release profile. After 24 hours, 
the amount of drug release from nanocapsules 
when exposed to intensity of 1W/cm2 was 
(22.6± 1.16) %. The 24-hour drug release at 
intensities of 0.3 and 0.5W/cm2 were (13.6± 
0.79) % and (17.7 ± 0.92) %, respectively.
Effect of Exposure Time
To evaluate the effect of ultrasound exposure 
time on the rate of drug release, we re-sorted 
our findings and re-plotted drug release profile 
from point of view of exposure time at certain 
intensity. Figure 6 demonstrates the amount of 
drug release versus time for the nanocapsules 
treated with the same frequency but different 
sonication period. Figure 6a shows the soni-
cation at intensity of 0.3 W/cm2; it is evident 
that an increase in ultrasound exposure time 
from 5 min to 10 min, significantly enhances 
the amount of released drug from (9.5± 0.63) 
% to (13.6± 0.79) %. Figure 6b shows the 
elevation of drug release at 0.5 W/cm2 for 5 
and 10-minute sonication period. As it can be 
seen, the amount of drug release 24 hours af-
ter ultrasound exposure significantly increased 
from (13.2± 0.81) % to (17.7± 0.92) %. Final-
ly, figure 6c presents the results obtained for 
ultrasound intensity at 1W/cm2 at two differ-
ent exposure times.  It illustrates that the per-
centage of drug released from nanocapsules 
has significantly increased (16.4± 0.93)% and 
Abed Z. et al
Group
Ultrasound parameter
(Exposure time and Intensity)
1 Control (No Exposure)
2
5 min
0.3 w/cm2
3 0.5 w/cm2
4 1 w/cm2
5
10 min
0.3 w/cm2
6 0.5 w/cm2
7 1 w/cm2
Table 1: Considered groups in this study
 
Figure 3: Size distribution of magnetic PLGA 
nanocapsules containing 5-Fu (Effective di-
ameter was approximately of 70 nm).
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Figure 4: TEM image of magnetic nanocapsules
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Figure 5a: Drug release profile of nanocapsules exposed by various ultrasound intensities for 
5min.
(22.6± 1.16)% for 5 min and 10 min exposure 
periods, respectively.
Discussion
Characteristics of Nanocapsules
The size of nanoparticles is of great impor-
tance in drug delivery, and influences their 
biodistribution profile [25]. This dependence 
is nonlinear and different from one organ to 
another. Table 2 presents a comparison be-
tween the synthesized nanocapsules in this 
study and nanocapsules reported by other re-
searchers. As it is seen in Table 2, the structure 
of nanocapsules affects the size of nanocap-
sules and encapsulation efficiency.
Application of Ultrasound in Drug Delivery
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Effect of Ultrasound Irradiation 
on Drug Release Profile
The results presented in this study show that 
ultrasound waves affect the profile of drug re-
lease from nanocapsules. To make an in-depth 
discussion, we present Table 3 to summarize 
what may be found according to Figures 5 and 
6. The ratios reported in Table 3 are calculated 
according to Equation 7:
  i
j
CREnhancement ratio
CR
=                      (7)
Where CRi is cumulative release in the pres-
ence of ultrasound and CRj is cumulative re-
lease in the absence of ultrasound. Based on 
Table 3, it may be inferred that the amount of 
Abed Z. et al
Figure 5b: Drug release profile of nanocapsules exposed by various ultrasound intensities for 
10 min.
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Reference Structure of nanocapsules Size(nm) Drug content(%)
Encapsulation 
efficiency(%)
Current study PLGA 70 46.4 5.8
Ashjari et al [28] PLGA 91-235 62-84 4.3-7.5
Wang et al [29] PLGA-Chitosan 197-340 28.6-24.1 22-28
Lei et al [30] PEG-PBLG* 230 61.5 27
Bruke et al [22] PLGA-BSA** 130 8 8
* PBLG: Poly-Benzyl L-Glutamate
**BSA: Bovine serum albumin
Table 2: A comparison between the characteristics of nanocapsules synthesized in current study 
and some other nanocapsules containing 5-Fu.
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Figure 6a: Drug release profile of nanocapsules exposed by ultrasound intensity of 0.3 W/cm2 
for 5 min and 10 min.
Figure 6b: Drug release profile of nanocapsules exposed by ultrasound intensity of 0.5 W/cm2 
for 5 min and 10 min.
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energy density delivered to the nanocapsules 
directly changes the amount of drug release. 
This finding is in agreement with results re-
ported in other studies.
Rappaport et al. studied the effect of ultra-
sound intensity on drug release from doxo-
rubicin- loaded polymeric micelles. They 
concluded that the intensity had a linear rela-
tionship with drug release so that the higher 
the intensity, the faster the rate of drug release. 
For example, the drug release is about 3% for 
1MHz frequency and 2W/cm2 intensity while 
it reaches about 8% for 6W/cm2 in the same 
frequency. It means that drug release increased 
2.6 folds [23]. 
In another study performed by Afadzi et 
al, the rate of drug release was investigated 
at different ultrasound intensities. They also 
showed that the drug release increased with 
increasing of intensity. For example, the drug 
release reaches about 60% for 2-minute expo-
sure and 57.24 W/cm2 whereas, the drug re-
lease was not as much for the same exposure 
time and 1.64 W/cm2 intensity [23].
Another parameter which affects the rate of 
drug release is ultrasound exposure time. It is 
obvious that the amount of delivered energy to 
nanocapsules in longer periods is higher. As 
a result, higher amounts of energy imparted 
to the medium cause turbulence into it influ-
encing the nanoparticle membrane. This may 
accelerate the rate of drug release from nano-
Abed Z. et al
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Figure 6c: Drug release profile of nanocapsules exposed by ultrasound intensity of 1 W/cm2 for 
5 min and 10 min.
Ultrasound parameter
((W/cm2)/min)
0.3/5 0.3/10 0.5/5 0.5/10 1/5 1/10
Enhancement ration 1.64 2.34 2.28 3.05 2.83 3.90
Table 3: Summary of enhancement ratios for cumulative drug release due to ultrasound irradia-
tion
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capsules. 
A similar result was reported by Cohen-levi 
et al. They demonstrated that the longer the 
ultrasound exposure time, the greater the drug 
release from liposome. They reported drug re-
lease reached 38% and 60% for 10 min and 
30 min ultrasound exposure, respectively [26].
In a study performed by Affadzi et al., the 
effect of ultrasound exposure time on the rate 
of drug release from Liposomes was investi-
gated. Keeping intensity constant, they dem-
onstrated that drug release was 30% for 20 
sec ultrasound exposure while this amount 
reached  60% for 120 sec exposure [27].
As stated in Introduction section, we have 
recently reported the effects of 3 MHz ul-
trasound irradiation on therapeutic ration of 
PLGA-based magnetic nanocapsules contain-
ing 5-Fu [17, 18]. Using an external magnetic 
field, we targeted the nanocapsules towards 
the induced colon tumors in BALB/c mice and 
reported significantly better results in compar-
ison with 5-Fu alone. We also demonstrated 
that the combination of magnetic drug target-
ing and ultrasound wave had significant effect 
on increasing the therapeutic ratio of nanocap-
sules [17, 18]. Considering the data obtained 
and discussed in the present study (Table 3), 
it may be concluded that ultrasound enhances 
cumulative drug release and consequently in-
creases the therapeutic ratio of nanocapsules 
in vivo.
Conclusion
In this study, we reported the effects of 3 
MHz ultrasound on the rate of drug release 
from PLGA nanocapsules. The results dem-
onstrated that drug release profile could be 
modified by controlling the physical parame-
ters of ultrasound waves. It was concluded the 
amount of drug released from nanocapsules 
significantly rose by increasing the exposure 
time and the intensity of ultrasound. This 
study may be a good indication to prove the 
high capabilities of ultrasound waves in the 
field of controlled release of drugs using novel 
nano-carriers.
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